허가사항 범위 내에서 아래와 같은 기준으로 투여 시 요양급여를 인정하며, 동 인정기준 이외에는 약값 전액을 환자가 부담토록 함.
- 아 래 -
이차성 부갑상선 기능항진증을 보이는 투석중인 만성신부전 환자로서 동 약제를 투여하기 전 혈청칼슘이 9.0mg/dL 이상이고 부갑상선호르몬(iPTH)이 300pg/mL 이상인 경우
- 다만, 동 약제 투여 중 부갑상선호르몬(iPTH)이 150pg/mL 이상인 경우 지속투여를 인정함.
■ 고시 개정 고시번호(시행일자)
고시 제2018-81호(2018.5.1.)
■ 고시 개정 사유
교과서, 가이드라인, 임상연구 논문 등을 반영하여, 투석중인 만성신부전환자의 이차성 부갑상선 기능항진증 치료에 일정 혈청칼슘 기준 수치(9.0㎎/㎗) 이상일 때 사용가능하도록 기준을 확대함
■ 관련문헌 등
？Harrison's Principles of Internal Medicine, 19e
？Goldman cecil medicine Twenty-Fifth Edition (2015)
？Brenner & Rector's the kidney, Tenth Edition> 2019-2033. e5 Copyright ⓒ 2016 by Elsevier
？KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney International Supplements (2017) 7, 1？59
？KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Am J of Kidney Dis., 2017
？The UK eCKD guide: CLINICAL PRACTICE GUIDELINE CKD-MINERAL AND BONE DISORDERS (CKD-MBD)
？Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder, Japanese Society for Dialysis Therapy and Japanese Society of Nephrology, Tokyo, Japan; Therapeutic Apheresis and Dialysis 2013
？Elder G, Faull R, Branley P, et al.: Caring for Australasians with Renal Impairment (CARI): Use of calcimimetic drugs. Nephrology 11 Suppl 1:S 240-4, 2006
？Jindal K, Chan CT, Deziel C, et al.: Canadian Society of Nephrology Committee for Clinical Practice Guidelines: Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol 17 Suppl 1:S1-27, 2006
？만성콩팥병 진료지침, 2008, 대한신장학회
？Sekercioglu N, Busse JW et, al. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2016 Jul;38(6):857-74.
？Li D, Shao L, Zhou H et, al. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine. 2013 Feb;43(1):68-77.
？Zhang Q, Li M, You L, Li H et, al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One. 2012;7(10):e48070.
？EVOLVE Trial Investigators, Chertow GM, Block GA et, al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012 Dec 27;367(26):2482-94.
？Taniguchi M, Fukagawa M et, al. Serum Phosphate and Calcium Should Be Primarily and Consistently Controlled in Prevalent Hemodialysis Patients. Therapeutic Apheresis and Dialysis 2013; 17(2):221？-228
？Hwang E, Choi BS et, al. Management of chronic kidney disease-mineral and bone disorder: Korean working group recommendations. Kidney Res Clin Pract. 2015 Mar;34(1):4-12
？Kwon YJ. Management of chronic kidney disease-mineral and bone disorder. 대한내과학회지: 제 86권 제 3호 2014